TAS2R20

Across TCGA pan-cancer cohorts, TAS2R20 RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of TAS2R20’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TAS2R20 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TAS2R20 is over-expressed in tumor, although a few such as UCEC show the opposite, repressed pattern.

KIRC, HNSC, and LIHC are the cancer types where TAS2R20 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TAS2R20 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.308	<.001	11	view →
HNSC	Female	All	+0.308	<.001	9	view →
LIHC	All	All	+0.137	<.001	6	view →
UCEC	All	All	−0.498	<.001	4	view →
CHOL	All	All	+0.858	<.001	2	view →
PAAD	Male	All	+0.489	.001	2	view →
READ	All	All	+0.402	.011	1	view →
STAD	All	All	+0.178	.040	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

TAS2R20–KIRC

Open the KIRC breakdown →